{"id":"dvs-233-sr","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Nausea"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Insomnia"},{"rate":"10-15","effect":"Sexual dysfunction"},{"rate":"10-15","effect":"Sweating"},{"rate":"5-10","effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venlafaxine works by inhibiting the reuptake of both serotonin and norepinephrine at the presynaptic neuron, thereby increasing their concentration in the synaptic cleft. The SR (sustained-release) formulation provides prolonged drug delivery, allowing for once-daily dosing and more stable plasma concentrations compared to immediate-release formulations. This mechanism is thought to restore neurotransmitter balance in mood disorders.","oneSentence":"DVS-233 SR is a sustained-release formulation of venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:22.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Social anxiety disorder"},{"name":"Panic disorder"}]},"trialDetails":[{"nctId":"NCT00831415","phase":"PHASE3","title":"Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":304},{"nctId":"NCT01190514","phase":"PHASE1","title":"Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Depression - Major Depressive Disorder","enrollment":41},{"nctId":"NCT01188668","phase":"PHASE4","title":"Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-08","conditions":"Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human","enrollment":38},{"nctId":"NCT01309542","phase":"PHASE3","title":"Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-08","conditions":"Major Depressive Disorder","enrollment":1403},{"nctId":"NCT00063206","phase":"PHASE3","title":"Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Major Depressive Disorder","enrollment":247},{"nctId":"NCT00092911","phase":"PHASE3","title":"Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Depression, Depressive Disorder, Major Depressive Disorder","enrollment":244},{"nctId":"NCT00087737","phase":"PHASE3","title":"Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Major Depressive Disorder","enrollment":369},{"nctId":"NCT00090649","phase":"PHASE3","title":"Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Major Depressive Disorder","enrollment":369},{"nctId":"NCT00242229","phase":"NA","title":"Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-10","conditions":"Major Depressive Disorder","enrollment":52},{"nctId":"NCT00075257","phase":"PHASE3","title":"Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Major Depressive Disorder","enrollment":603},{"nctId":"NCT00073762","phase":"PHASE3","title":"Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Major Depressive Disorder","enrollment":375},{"nctId":"NCT00072774","phase":"PHASE3","title":"Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Major Depressive Disorder","enrollment":480},{"nctId":"NCT00195546","phase":"PHASE3","title":"Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-04","conditions":"Menopause","enrollment":465},{"nctId":"NCT00452595","phase":"PHASE3","title":"Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT00421031","phase":"PHASE3","title":"Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2003-12","conditions":"Vasomotor Symptoms","enrollment":540},{"nctId":"NCT00256685","phase":"PHASE3","title":"Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-09","conditions":"Menopause, Hot Flashes, Sleep Disorders","enrollment":568}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DVS-233 SR","genericName":"DVS-233 SR","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DVS-233 SR is a sustained-release formulation of venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases synaptic levels of serotonin and norepinephrine by blocking their reuptake. Used for Major depressive disorder, Generalized anxiety disorder, Social anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}